The impact of the "low molecular weight heparin" administration on the clinical course of COVID-19 disease.

BACKGROUND: Lymphopenia is the most important criterion of the mortality and discharging feature for patients infected with coronavirus disease 2019 (COVID-19). This study aimed to investigate the clinical impact of a low molecular weight heparin (LMWH) treatment on the clinical course of COVID-19. MATERIALS AND METHODS: Patients? clinical symptoms, radiologic outcomes, hematologic, biochemical, D-dimer, and C-reactive protein (CRP) results were obtained from medical records. Participants were separated into two groups: one was treated with LMWH and the other was not. Improvement in the patients was compared before and after treatment. RESULTS: Ninety-six patients who were diagnosed with COVID-19 between April and May 2020 were retrospectively analyzed. The multivariable analysis showed that the count of lymphocytes, D-dimer, and CRP levels were significantly improved in the LMWH group, as compared to the control group (OR, (95% CI) 0.628 (0.248?0.965), p < 0.001), OR, (95% CI) 0.356 (0.089?0.674), p < 0.001, respectively). The area under the receiver operating characteristic (ROC) curve analysis was AUC: 0.679 ± 0.055, 0.615 ± 0.058, 0.633 ± 0.057, respectively, the s value was found as -1.032, -0.026, and -0.465, respectively. CONCLUSION: LMWH treatment group demonstrated better laboratory findings, including a recovery in the lymphocyte count, CRP, and D-dimer results.